Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated data from the CheckMate 9ER trial of patients with advanced renal cell carcinoma in the second article of a 2-part series.
The efficacy of immunotherapy for clear cell renal cell carcinoma (ccRCC), especially advanced ccRCC, is limited, presenting a clinical challenge. This limitation is closely tied to the immune regulation network. Understanding the heterogeneity of the tumour microenvironment (TME) is crucial ...
Nivolumab plus tivozanib did not improve progression-free survival in patients with advanced metastatic renal cell carcinoma after prior immune checkpoint inhibition.
Telix must resubmit the BLA with remediations in order to advance the application to full review, which the company expects to be able to complete within approximately 90 days.
Liquid biopsies are emerging as an alternative source for pediatric cancer biomarkers with potential applications during all stages of patient care, from diagnosis to long-term follow-up. While developments within this field are reported, these mainly focus on dedicated items such as a ...
Chen Wang and colleagues develop a forward-viewing optical coherence tomography endoscope for differentiating tumor tissues in renal biopsy. In conjunction with a convolutional neural network developed by the team, tissue recognition rates of over 99% were achieved.
Understanding the unique traits of a rare kidney cancer type, TFE3-rearranged renal cell carcinoma, is important due to its poor response to usual treatments. This study explores the genetic and metabolic makeup of tRCC, comparing it with clear cell RCC and normal kidney cells. Using a mix of ...
The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma.
The progression-free survival benefit with belzutifan was observed across subgroups of patients with pretreated advanced clear cell renal cell carcinoma.
Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.